Enfermedad pulmonar intersticial fibrosante progresiva (EPI-FP)
Effect of nintedanib on progression of interstitial lung disease (ILD) in patients with autoimmune disease-related ILDs: further data from the INBUILD trial
Matteson et al.
Nintedanib dose adjustments and adverse events in patients with progressive autoimmune disease-related interstitial lung diseases in the INBUILD trial
Volkmann et al.
Efficacy and safety of nintedanib in patients with autoimmune disease-related interstitial lung disease treated with DMARDs and/or glucocorticoids at baseline
Aringer et al.
